Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Scotiabank Downgrades INmune Bio to Sector Underperform, Lowers Price Target to $0.6

Author: Benzinga Newsdesk | July 01, 2025 08:02am
Scotiabank analyst George Farmer downgrades INmune Bio (NASDAQ:INMB) from Sector Outperform to Sector Underperform and lowers the price target from $23 to $0.6.

Posted In: INMB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist